pharma news today glp-1 obesity drugs today Agonists Weight Loss Market Report, 2025-2030 GLP-1 drugs transform obesity care,
Description
Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: randomized control study
A statistically significant improvement in fibrosis was also observed
Weight loss and GLP-1RAs are contraindications for patients with bulimia nervosa, as well as for those with low-frequency and/or limited-duration bulimia nervosa
It further examines actions insurers might take to benefit policyholders while maintaining a sustainable portfolio
placebo users
